HomeIndustriesMerck Raises Full-Year Forecast After Beating Q2 Estimate

Merck Raises Full-Year Forecast After Beating Q2 Estimate

Merck & Co decided to raise its full-year revenue forecast on Tuesday after posting better-than-expected financial results for the second quarter. Shares in the company rose by 1% in premarket trading on Tuesday morning.

Sales for Q2 were $15 billion, up from $14.6 billion during the same quarter a year ago. This comes despite a sharp decline in demand for the company’s COVID-19 therapeutic Lagevrio.

Keytruda drug sales for the quarter were $6.3 billion, outpacing the $5.9 billion forecasted by analysts. Sales for the cancer prevention drug Gardasil have surged by 47% to $2.5 billion. In contrast, sales of Lagevrio plummeted from $1.2 billion a year ago to $200 million today.

Despite positive revenue data, the company reported a quarterly adjusted loss of $5.2 billion, or $2.06 a share. This is primarily because of the $10.2 billion forked out by Merck to acquire Prometheus Biosciences. Even with this major expense, the company’s loss still beat analysts’ expectations of a $2.18 loss per share.

Merck now expects full-year sales in the range of $58.6 to $59.6 billion; up from its previous forecast of $57.7 billion to $58.9 billion.

Warren Buffett to Step Down as Berkshire Hathaway CEO at the End of 2025

Warren Buffett is ready to step down as the CEO of multinational conglomerate Berkshire Hathaway. Buffet announced his decision while speaking at the company’s...

Microsoft Stock Soars on Better-Than-Expected Q3 Earnings

Microsoft reported better-than-expected third-quarter earnings on Wednesday, which caused the company's stock to soar by more than 8% in after-hours trading. Microsoft reported $3.46 in...

Gold Continues to Drop From Record Highs, Dollar Ends Its Slide

After reaching fresh record highs at the beginning of last week, gold has been in the midst of a continuous drop. Meanwhile, the U.S....